CXCL4: A new biomarker of diagnosis and severity in systemic sclerosis?

被引：0
|
作者：
Marie, I. [1 ]
机构：
[1] CHU Rouen, Dept Med Interne, F-76031 Rouen, France
来源：
REVUE DE MEDECINE INTERNE | 2015年 / 36卷 / 02期
关键词：
Systemic sclerosis; Dendritic cells; CXCL4; Pathophysiology; Diagnosis; Prognosis; Therapy; PROTEOME-WIDE ANALYSIS; GROWTH-FACTOR-BETA; PLATELET FACTOR-IV; OCCUPATIONAL-EXPOSURE; CHEMOKINE PRODUCTION; DENDRITIC CELLS; PLATELET-FACTOR-4; SCLERODERMA; ACTIVATION; DISEASE;
D O I：
10.1016/j.revmed.2014.10.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：69 / 72
页数：4
相关论文
共 50 条
  • [41] New Biomarker for the Early Diagnosis of Multiple Sclerosis
    不详
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (16) : 1001 - 1001
  • [42] Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?
    van Bon, Lenny
    Cossu, Marta
    Scharstuhl, Alwin
    Pennings, Bas W. C.
    Vonk, Madelon C.
    Vreman, Hendrik J.
    Lafyatis, Robert L.
    van den Berg, Wim
    Wagener, Frank A. D. T. G.
    Radstake, Timothy R. D. J.
    RHEUMATOLOGY, 2016, 55 (11) : 2066 - 2073
  • [43] Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Roth, Michael D.
    Clements, Philip J.
    Khanna, Dinesh
    Furst, Daniel E.
    Mayes, Maureen
    Charles, Julio
    Tseng, Chi-Hong
    Elashoff, Robert M.
    Assassi, Shervin
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [44] Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
    Elizabeth R. Volkmann
    Donald P. Tashkin
    Michael D. Roth
    Philip J. Clements
    Dinesh Khanna
    Daniel E. Furst
    Maureen Mayes
    Julio Charles
    Chi-Hong Tseng
    Robert M. Elashoff
    Shervin Assassi
    Arthritis Research & Therapy, 18
  • [45] CXCL4 Contributes to the Pathogenesis of Chronic Liver Allograft Dysfunction
    Li, Jing
    Liu, Bin
    Shi, Yuan
    Xie, Ke-Liang
    Yin, Hai-Fang
    Yan, Lu-nan
    Lau, Wan-yee
    Wang, Guo-Lin
    JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [46] SEMAPHORIN 3A, AN IMMUNOREGULATOR AND POTENTIAL BIOMARKER FOR DISEASE SEVERITY IN SYSTEMIC SCLEROSIS
    Vadasz, Z.
    Rimar, D.
    Toubi, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : A61 - A61
  • [47] Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion
    Xiao, Zhihua
    Visentin, Gian P.
    Dayananda, Kannayakanahalli M.
    Neelamegham, Sriram
    BLOOD, 2008, 112 (04) : 1091 - 1100
  • [48] CXCL4及其受体与结直肠肿瘤
    晁红雷
    汪昱
    国际肿瘤学杂志, 2013, 40 (05) : 362 - 365
  • [49] Interaction of PF4 (CXCL4) with the vasculature: A role in atherosclerosis and angiogenesis
    Aidoudi, Sallouha
    Bikfalvi, Andreas
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (05) : 941 - 948
  • [50] SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis
    Hoeppner, Jakob
    Casteleyn, Vincent
    Biesen, Robert
    Rose, Thomas
    Windisch, Wolfram
    Burmester, Gerd Ruediger
    Siegert, Elise
    PHARMACEUTICALS, 2022, 15 (10)
12345